Tutorial
These icons indicate there is something to be interacted with. Click it when you see it.
Tutorial
These icons indicate there is something to be interacted with. Click it when you see it.
Tutorial
These icons indicate there is something to be interacted with. Click it when you see it.
touchIN CONVERSATION
A relaxed discussion between two faculty focussed on real world clinical issues. Useful tips below will show how to navigate the activity. Join the conversation.
Close
A relaxed discussion between two faculty focussed on real world clinical issues. Useful tips below will show how to navigate the activity. Join the conversation.
Close
Selecting ART: Working with people living with HIV to find the best regimen
Learning Objectives
After watching this activity, participants should be better able to:
- Compare antiretroviral treatment regimens and the implications these differences may have on patients
- Appraise best practices for shared decision-making when selecting antiretroviral therapies
- Assess the burden of antiretroviral treatment and the need to change regimen to optimize quality of life
Overview
In this activity, two HIV experts answer questions from healthcare professionals on how to navigate antiretroviral therapy (ART) options for people living with HIV. They discuss available ART regimens and criteria for treatment selection, best practices for shared decision-making and how to address treatment dissatisfaction.
This activity is provided by touchIME.
Target Audience
This activity has been designed to meet the educational needs of primary care physicians, HIV specialists, infectious disease specialists, genitourinary medicine specialists, specialist nurse practitioners and virologists involved in the management of HIV.
Faculty
Dr Tristan Barber discloses: Advisory board or panel fees from Gilead Sciences, Janssen, MSD and ViiV Healthcare. Consultancy fees from Gilead Sciences, Janssen, MSD and ViiV Healthcare. Grants/research support from Gilead Sciences, Roche and ViiV Healthcare. Speaker’s bureau fees from Gilead Sciences, Janssen, MSD and ViiV Healthcare.
Dr Christoph Boesecke discloses: Advisory board or panel fees from AbbVie, Gilead Sciences, Johnson & Johnson, MSD, Pfizer and ViiV Healthcare. Consultant fees from AbbVie, Gilead Sciences, Johnson & Johnson, MSD, Pfizer and ViiV Healthcare. Grants/research support from DZIF, Hector Foundation, NEAT ID. Speaker’s bureau fees from AbbVie, AstraZeneca, Bavarian Nordic, Gilead Sciences, Johnson & Johnson, MSD, Pfizer and ViiV Healthcare.
Touch Medical Contributors
Adriano Boasso has no financial interests/relationships or affiliations in relation to this activity.
Date of original release: 15 August 2024.Â
To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.
Claim CreditYou may also be interested in...
CONFERENCE HUB
Pioneering HIV vaccine research through regional advances and vaccine equity
touchIN CONVERSATION
Practical considerations for COVID-19 vaccination in Africa
This activity is CE/CME accredited
JOURNALS
Dapivirine Vaginal Ring for HIV Prevention in Women in South Africa
JOURNALS
Letter from the Editor-in-Chief
CONFERENCE HUB
Anchalee Avihingsanon, AIDS2022: Bictegravir/FTC/TAF vs dolutegravir in HIV/HBV coinfected adults – ALLIANCE study interim results
touchMDT
From PrEP to long-term ART in HIV: Overcoming barriers to adherence throughout the journey
REGISTER NOW FOR FREE ACCESS TO
- 1000+ topical and insightful peer-reviewed journal articles
- 100+ hours of bite-sized congress highlights
- 10 major therapy areas packed with the latest scientific advances
- 150+ specialties offering learn-on-the-go medical education
- + Concise email updates and newsletters so you never miss out
